International Journal of Molecular Sciences (May 2024)

Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis

  • Michelle Yi,
  • Arvin John Toribio,
  • Yusuf Muhammad Salem,
  • Michael Alexander,
  • Antoney Ferrey,
  • Lourdes Swentek,
  • Ekamol Tantisattamo,
  • Hirohito Ichii

DOI
https://doi.org/10.3390/ijms25115831
Journal volume & issue
Vol. 25, no. 11
p. 5831

Abstract

Read online

Diabetes mellitus (DM) is a chronic endocrine disorder that affects more than 20 million people in the United States. DM-related complications affect multiple organ systems and are a significant cause of morbidity and mortality among people with DM. Of the numerous acute and chronic complications, atherosclerosis due to diabetic dyslipidemia is a condition that can lead to many life-threatening diseases, such as stroke, coronary artery disease, and myocardial infarction. The nuclear erythroid 2-related factor 2 (Nrf2) signaling pathway is an emerging antioxidative pathway and a promising target for the treatment of DM and its complications. This review aims to explore the Nrf2 pathway’s role in combating diabetic dyslipidemia. We will explore risk factors for diabetic dyslipidemia at a cellular level and aim to elucidate how the Nrf2 pathway becomes a potential therapeutic target for DM-related atherosclerosis.

Keywords